Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostatic Cancer”

329 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 329 results

Not applicableUnknownNCT02208583
What this trial is testing

Molecular Phenotype Changes and Personalized Treatment for CRPC

Who this might be right for
Hormone Refractory Prostate Cancer
Tianjin Medical University Cancer Institute and Hospital 150
Testing effectiveness (Phase 2)Ended earlyNCT00176631
What this trial is testing

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
Rutgers, The State University of New Jersey 10
Large-scale testing (Phase 3)Study completedNCT00069745
What this trial is testing

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Who this might be right for
Prostate CancerHormone Refractory Prostate Cancer
Agennix
Testing effectiveness (Phase 2)UnknownNCT00218205
What this trial is testing

Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Who this might be right for
Prostate Cancer
Department of Veterans Affairs, New Jersey 28
Early research (Phase 1)Study completedNCT00005627
What this trial is testing

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Dana-Farber Cancer Institute
Early research (Phase 1)Study completedNCT01324583
What this trial is testing

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 48
Testing effectiveness (Phase 2)Study completedNCT01487863
What this trial is testing

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer
Dendreon 69
Testing effectiveness (Phase 2)Ended earlyNCT00126230
What this trial is testing

Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris 55
Testing effectiveness (Phase 2)Study completedNCT00193193
What this trial is testing

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Who this might be right for
Prostate Cancer
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Ended earlyNCT01450683
What this trial is testing

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Who this might be right for
Prostate CancerProstatic NeoplasmsCastrate-resistant Prostate Cancer (CRPC)+3 more
Stanford University 4
Not applicableWithdrawnNCT02867345
What this trial is testing

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Peking University
Testing effectiveness (Phase 2)Study completedNCT00006002
What this trial is testing

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
University of Chicago 36
Testing effectiveness (Phase 2)Ended earlyNCT00525408
What this trial is testing

Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Cadila Pharnmaceuticals 134
Testing effectiveness (Phase 2)Study completedNCT00394810
What this trial is testing

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
CASI pharmaceuticals, Inc. 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955082
What this trial is testing

The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment

Who this might be right for
Hormone Refractory Prostate Cancer
Institute of Cancer Research, United Kingdom 305
Testing effectiveness (Phase 2)Ended earlyNCT00479635
What this trial is testing

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Cortice Biosciences, Inc. 26
Testing effectiveness (Phase 2)Study completedNCT01518283
What this trial is testing

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Spanish Oncology Genito-Urinary Group 74
Large-scale testing (Phase 3)Ended earlyNCT00450970
What this trial is testing

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Who this might be right for
Prostate Cancer
Agennix 344
Testing effectiveness (Phase 2)Study completedNCT00831467
What this trial is testing

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

Who this might be right for
Hormonal Refractory Prostate Cancer
CureVac 48
Testing effectiveness (Phase 2)Study completedNCT00331344
What this trial is testing

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 100
Load More Results